Awardee OrganizationUNIVERSITY OF CALIFORNIA LOS ANGELES
Description
Abstract Text
PROJECT SUMMARY/ABSTRACT
Over 43M Americans (~13% of the population) will suffer from social anxiety disorder in their lifetime
(Kessler et al., 2012) – 20M of which will have fear of public speaking (Kessler et al., 1998). Cognitive-behavioral
therapy (a major component of which is exposure therapy) is a leading treatment for social anxiety disorder but
is only fully effective in ~45% of individuals (Loerinc, et al., 2015). Exposure therapy is the clinical proxy of
Pavlovian extinction in which the individual approaches their feared situation (e.g., social situation) without the
expected aversive outcome (e.g., negative social judgment). Several basic research findings show that stronger
reward processing is linked to better extinction of fear, suggesting that enhancing reward processing can improve
exposure therapy. First, reward processing is involved in extinction learning at the time of omission of an
expected aversive outcome, such that the omission is experienced as “relief-pleasantness” as measured by self-
report and by neural mechanisms of reward processing (e.g., Lange, et al., 2020). Second, direct stimulation of
the reward circuitry has been shown to enhance extinction of fear (Sierra, et al., 2023). Third, low self-reported
reward processing is associated with low relief-pleasantness (Leng, et al., 2022). Fourth, social anxiety disorder
is associated with poor reward processing (Cremers, et al., 2015). Lastly, anhedonia – a robust correlate of poor
reward processing and social anxiety – is associated with poor extinction of fear (Young, et al., 2021). Thus,
enhancing reward processing may be especially likely to improve exposure therapy outcomes in social anxiety
disorder (Aim 1) by increasing relief-pleasantness when an expected aversive event does not occur (Aim 2). In
this K23, we will conduct the first experimental therapeutics study investigating the effects of target engagement
(reward processing) on subsequent exposure therapy outcome (social anxiety; specifically, fear of public
speaking). To this end, socially anxious participants with a fear of public speaking and low reward processing
will undergo the behavioral portion of Positive Affect Treatment (PAT-B) or Relaxation Treatment; both
treatments are expected to decrease negative affect, but PAT-B is expected to improve reward processing more
than Relaxation Treatment (Craske et al., 2023). Subsequently, all participants will undergo Exposure Therapy
for fear of public speaking with the primary outcome being multi-modal assessment of public speaking anxiety.
For experimental therapeutics, the target is reward processing, which we will measure primarily as relief-
pleasantness in fMRI fear conditioning during extinction at the time of electric shock omission (measured neurally
and with computational modeling of self-report relief-pleasantness). The training plan will help the Candidate
gain expertise in experimental therapeutics, fMRI, and computational modeling in the service of his career goal:
to improve our understanding and treatment of anxiety disorders. This K23 may improve the efficacy of exposure
therapy, our understanding of its mechanisms, and help millions of people with social anxiety disorder.
Public Health Relevance Statement
Project Narrative
Over 43 million Americans (~13% of the population) will suffer from social anxiety disorder at some point
in their lives (Kessler, et al., 2012), but a leading form of treatment (cognitive-behavioral therapy, a major
component of which is exposure therapy) is only fully effective in approximately 45% of individuals (Loerinc, et
al., 2015). Critically, based on robust basic scientific research in the animal and human literatures, there is strong
reason to believe that improving reward processing will enhance i) relief-pleasantness when an expected
aversive outcome does not occur, ii) Pavlovian extinction of fear, and iii) exposure therapy outcome. In this K23,
we will investigate the effects of Positive Affect Treatment (designed to increase reward processing) vs
Relaxation Treatment (control condition) on subsequent exposure therapy outcome (fear of public speaking) for
socially anxious individuals who have a fear of public speaking and low reward processing while measuring the
treatment mechanism (reward processing) before, during, and after treatment.
NIH Spending Category
No NIH Spending Category available.
Project Terms
AffectAftercareAmericanAnhedoniaAnimalsAnxietyBasic ScienceBehavior TherapyBehavioralBrainClinicalCognitive TherapyComputer ModelsCorpus striatum structureDopamineEventExtinctionFoodFrightFunctional Magnetic Resonance ImagingGoalsHobbiesHumanIndividualInvestigational TherapiesJudgmentLinkLiteratureMeasuresMediatingMethodsNational Institute of Mental HealthOutcomeParticipantPatient Self-ReportPersonsPopulationPreventionProxyPublic SpeakingRandomizedRandomized, Controlled TrialsRelaxationResearchRewardsScientistServicesShockSocial Anxiety DisorderSpeechStrategic PlanningTherapeutic StudiesTimeTrainingTranslational ResearchTreatment outcomeWorkanxiousanxious individualscareerconditioned feardesignexperienceimprovedindexinginsightlearning extinctionmultimodalitynegative affectneuralneuromechanismnovelprimary outcomepsychologicrecruitreward circuitryreward processingskillssocialsocial anxietysocial situationsuccesstherapy outcometreatment of anxiety disorders
No Sub Projects information available for 1K23MH133971-01A1
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 1K23MH133971-01A1
Patents
No Patents information available for 1K23MH133971-01A1
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 1K23MH133971-01A1
Clinical Studies
No Clinical Studies information available for 1K23MH133971-01A1
News and More
Related News Releases
No news release information available for 1K23MH133971-01A1
History
No Historical information available for 1K23MH133971-01A1
Similar Projects
No Similar Projects information available for 1K23MH133971-01A1